Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005.
about
Partisan perspectives in the medical literature: a study of high frequency editorialists favoring hormone replacement therapy.The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic CancerBisphosphonates and evidence for association with esophageal and gastric cancer: a systematic review and meta-analysis.Carpal Tunnel Syndrome Associated with Oral Bisphosphonates. A Population-Based Cohort StudyCharacteristics and recent evolution of menopausal hormone therapy use in a cohort of Swedish womenLong-term effect of the Women's Health Initiative study on antiosteoporosis medication prescribingHormone replacement therapy, oral contraceptive use, and distal large bowel cancer: a population-based case-control study.Oral bisphosphonate use and breast cancer incidence in postmenopausal women.Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort.Bisphosphonates and risk of upper gastrointestinal cancer--a case control study using the General Practice Research Database (GPRD).Breast cancer risk in relation to the interval between menopause and starting hormone therapy.Interval cancers in the NHS breast cancer screening programme in England, Wales and Northern Ireland.Postmenopausal hormone therapy and breast cancer risk: current status and unanswered questions.Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.10. Cancers attributable to exposure to hormones in the UK in 2010.Exposure to bisphosphonates and risk of cancer: a protocol for nested case-control studies using the QResearch primary care database.Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000-2010Exposure to oral bisphosphonates and risk of esophageal cancer.Exposure to oral bisphosphonates and risk of cancer.Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort studyExogenous and endogenous hormones and breast cancer.The Effects of Age, Adiposity, and Physical Activity on the Risk of Seven Site-Specific Fractures in Postmenopausal Women.Bisphosphonate use and risk of colorectal cancer: a systematic review and meta-analysis.Trends in oral anti-osteoporosis drug prescription in the United Kingdom between 1990 and 2012: Variation by age, sex, geographic location and ethnicityOsteoporosis in 2010: building bones and (safely) preventing breaks.Colorectal cancer in women: hormone replacement therapy and chemoprevention.Estrogen alone and health outcomes in black women by African ancestry: a secondary analyses of a randomized controlled trial.Differences in breast cancer incidence in Australia and England by age, extent of disease and deprivation status: women diagnosed 1980-2002.Estimating age-specific trends in circulating testosterone and sex hormone-binding globulin in males and females across the lifespan.The efficacy and safety of vertebral fracture prevention therapies in post-menopausal osteoporosis treatment: Which therapies work best? a network meta-analysis.Hormone replacement therapy and incidence of central nervous system tumours in the Million Women Study.Breast cancer incidence and use of hormone therapy in Denmark 1978-2007.Bisphosphonates, healthcare professionals and oral health.Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial.Measuring the impact of medicines regulatory interventions - Systematic review and methodological considerations.Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study.The risk of major and any (non-hip) fragility fracture after hip fracture in the United Kingdom: 2000-2010.Denosumab - a new medication in the treatment of postmenopausal osteoporosis.Five Decades of Hormone Therapy Research: The Long, the Short, and the InconclusiveBisphosphonates and esophageal cancer—a pathway through the confusion
P2860
Q24289488-41DF654C-CEE6-4D4E-9AD1-D49DF3FD70DCQ26738873-8C446EC9-A284-40E2-99E2-741482BEEEF0Q27693291-BDB49718-4AE1-4D0E-A22A-925540CABFF3Q28384121-5D0D57DC-9205-4672-851F-981B622EE983Q33710365-C945B1EA-3509-4D21-996B-90AF63D4195DQ33874953-84F76FA0-DF78-4D49-A110-C66C45351737Q34047699-A87E7DB3-7021-450C-BA64-2BD9164E9E30Q34049239-4CD34F77-0836-4B9A-A8B5-DBC14096269AQ34104102-FFC26E68-B566-49A6-B68E-B85B4CF434CAQ34462218-814C4547-4F07-458F-AE22-E84F636A3557Q34577224-75D20FB6-4448-4F40-A754-E0D4C862A558Q34627966-C2C037E6-133D-4436-8603-58A6FCB2EDFEQ35196707-B7EABDC2-AB99-4EFE-A315-40309E8244BEQ35215353-BB632369-08D4-4E8C-AE71-8DC7331E01A4Q35654702-D7814191-0D3A-42AA-915E-B1686C382049Q35753917-0F0D5CC7-741D-4776-8940-0ABF0D716426Q35789242-462CB357-E16F-4E19-8B3C-A4F941887C38Q36441868-E4AAEF53-0913-487F-8EA9-3CFD8A0F9794Q36455050-E8B26694-6AA2-47CA-AAB8-798D9775B090Q36818049-4AA91CB0-A941-4CD1-8D44-C02D9E9FAC3AQ37008462-DC2DD0AB-6600-478A-9581-5D98DCFC16EDQ37152286-B06D2533-764F-4DAF-B32E-38992AAAF258Q37161879-16C0CF16-D6A0-46C2-8E27-613ED632E415Q37443313-BC5E4D8D-A1F6-466B-8C8D-1F3275E69DB2Q37834959-D30919C7-DF93-4C63-8BAF-66759B03A545Q38011783-DBEC2338-5A2A-47D5-A5DA-ECF51FD01B7CQ38982905-913519E7-5AF1-4142-B185-A2D0DBDC11ACQ39602524-1E0C11F0-3119-437E-9597-8D756FD32366Q40464678-901AA4D2-7AF1-4E50-A62C-0B6332B7E840Q41204558-A2A4C91A-79CA-470D-9CDE-12851697A834Q43887706-3A537DE7-165B-4AB7-8E61-62376D057F59Q44395164-3A39DE36-8990-4B23-8F7F-30B6C1A56E34Q45209793-710749FB-FF0B-4AB5-863A-46FA86DD70ABQ46393065-D0EA620A-C00B-4D78-B9F6-4AF5E1588BEAQ47653552-AF53F7DF-ADB4-4527-BA18-DCA03B380902Q50490968-D8874661-949A-4AF6-95C7-5AF8B79CBACAQ51129452-00B0D76C-FC0E-4EEC-8A83-8CAA92D2A16AQ52673042-C648D3BC-03E7-4FE6-88CA-43F655710216Q56673117-F108F71F-E044-431E-B5AF-71198865C095Q56969664-849E63C4-04D4-446B-9725-2D9C9588CFEF
P2860
Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Prescribing of hormone therapy ...... the UK between 1991 and 2005.
@ast
Prescribing of hormone therapy ...... the UK between 1991 and 2005.
@en
Prescribing of hormone therapy ...... the UK between 1991 and 2005.
@nl
type
label
Prescribing of hormone therapy ...... the UK between 1991 and 2005.
@ast
Prescribing of hormone therapy ...... the UK between 1991 and 2005.
@en
Prescribing of hormone therapy ...... the UK between 1991 and 2005.
@nl
prefLabel
Prescribing of hormone therapy ...... the UK between 1991 and 2005.
@ast
Prescribing of hormone therapy ...... the UK between 1991 and 2005.
@en
Prescribing of hormone therapy ...... the UK between 1991 and 2005.
@nl
P1476
Prescribing of hormone therapy ...... the UK between 1991 and 2005.
@en
P2093
Jane Green
Lesley Wise
P2888
P304
P356
10.1007/S00228-007-0320-6
P577
2007-06-28T00:00:00Z
P6179
1015653538